Reconsidering clindamycin–rifampicin use in hidradenitis suppurativa: balancing anti-inflammatory benefits and resistance risk
Sibel Altunışık Toplu, Nihal Altunışık
Clinical and Experimental Dermatology · 2025-07
Abstract
We read with great interest the article by Wainman et al., entitled ‘Is there still a role for clindamycin and rifampicin in the treatment of hidradenitis suppurativa? A review of the literature’. We would like to contribute to this important discussion by offering additional clinical perspectives.
MeSH terms
- Hidradenitis suppurativa
- Clindamycin
- Medicine
- Rifampicin
- Resistance (ecology)
- Dermatology
- Antibiotics
- Intensive care medicine